Cancer immunotherapy vaccine

This page covers all Cancer immunotherapy vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway.

Targets

Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway

Marketed (1)

• LI · CEL-SCI Corporation · Oncology
  LI is an immunotherapeutic agent designed to enhance immune response against cancer cells.

Phase 3 pipeline (3)

• HyperAcute-Pancreas Immunotherapy · NewLink Genetics Corporation · Oncology
  HyperAcute-Pancreas is an immunotherapy that activates the patient's immune system to recognize and attack pancreatic cancer cells by combining a tumor-associated antigen vaccine with an immune checkpoint inhibitor.
• IMM-101 · Immodulon Therapeutics Ltd · Oncology
  IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity.
• AScVS + Prazosin · Haffkine Bio-Pharmaceutical Corporation Ltd. · Oncology
  AScVS is an autologous stem cell vaccine that stimulates immune responses against cancer, combined with prazosin, an alpha-1 adrenergic antagonist that may enhance immune function.

Patent intelligence

• cancer immunotherapy vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates